bpc-157 anti-inflammatory effects tnf-α il-6 cox-2 Anti-TNF-α therapies: the next generation Anti-TNF biologic agents: still the

In response to our concerns, the applicant commented that it is committed to providing the clinical evidence necessary to satisfy the substantial clinical improvement standard and indicated that it is currently conducting an ongoing prospective, multicenter, open-label, single-arm clinical study [44] to evaluate the Axoguard HA+ Nerve Protector TM in patients undergoing a first revision cubital tunnel decompression procedure for recurrent or recalcitrant cubital tunnel syndrome

It depends on the area youre looking to treat

Secondly, this study is an observational study, and therefore, the causality could not be concluded

El BPC-157 ha demostrado estimular este proceso en estudios con animales